3D bioprinting and tissue engineering specialist Aspect Biosystems has entered a research collaboration with Johnson & Johnson's DePuy Synthes to create bioprinted knee meniscus tissue suitable for surgical therapy. It is one of more than 50 commercial and academic partnerships J&J has entered to develop complementary technologies and materials for its medical devices.
Johnson & Johnson's orthopedics business DePuy Synthes will use Aspect Biosystems Ltd.'s Lab-on-a-Printer 3D bioprinting platform to develop a bioprinted tissue device for surgical knee meniscus replacement.
Aspect CEO Tamer Mohamed told Medtech Insight that Lab-on-a-Printer is highly differentiated from other 3D-printing technologies because it offers the unique capability of creating complex multi-cellular 3D tissues at "industrially relevant throughput
Global investment in consumer healthtech increased by 9% year-over-year in 2024, totaling $4.5bn, with significant interest in mental health solutions, according to Galen Growth. While the first quarter of 2025 saw raised confidence and investments, the Trump administration’s new tariffs and sweeping changes to healthcare have introduced new uncertainties.
A patient, Dena Lawler, is suing Boston Scientific and the US FDA over alleged harm from a spinal stimulator device. Lawler claims inadequate regulatory review allowed dangerous modifications to the device, which then caused her pain and other health issues. She is calling for reconsideration of the device approvals.
At AAOS, orthopedics players showcased their latest robotic-assisted platforms, power tools, 3D printed technologies and software offerings. This article brings you highlights from interviews Medtech Insight conducted on site with representatives from J&J, Stryker, Materialise and Canary Medical.
Enovis has named veteran medtech leader Damien McDonald as its new CEO effective 12 May as the orthopedic company reaffirms first-quarter 2025 revenue guidance of between $555m and $563m. Medtech Insight spoke with Tim Czartoski, Enovis’ president of US surgical and global product and enabling technologies, about the firm’s growth strategy and innovation plans.
